Authors


Matt Harrington

Latest:

Identifying Integrated Digital Platforms Designed for a Decentralized Future

COVID-19 forces sponsors to take new approach for assessing trial support models.


Martin Brown

Latest:

Harnessing the Power of Scientific Surveillance

Statistical methods used via this technique in centralized monitoring.


Henry McNamara

Latest:

Five Areas That Will Define the Future of Clinical Trials

Following COVID-19, companies are focused on solutions offering the latest technology and most value to patients.


Norman M. Goldfarb

Latest:

Let’s Destroy Our Obsolete Paper Study Records

Although there are much larger problems in clinical research, storing obsolete study records is a totally unnecessary cost.


Yuxiao Wang

Latest:

Survey Results: GCP Quality and Risks in Decentralized Clinical Trials

Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.


Pam Verhoff

Latest:

Recruiting Trial Workers Amidst Growing Complexity

Economic challenges combined with increased responsibility for clinical trial workers has shifted talent recruitment.


Siti Nur Hafizah Binti Adnan

Latest:

A View of Electronic Signature in Clinical Trial Agreements in Malaysia

A focus on the position of law for e-signatures, their benefits, and the role of Clinical Research Malaysia in educating the industry on the practicality of e-signature.


Stephen Le Breton

Latest:

COVID-19 and Its Impact on the Future of Clinical Trial Execution

Findings from a Tufts study examining the effects of COVID-19 on clinical trials.



Piet van der Graaf, PharmD, PhD

Latest:

Upping the Ante for Predicting the Success of Alzheimer Disease Treatments

The use of modeling and biosimulation can help predict potential outcomes and improve confidence in therapeutic candidates for Alzheimer disease.


Ramji Vasudevan

Latest:

How AI is Changing Early Drug Development

Though artificial intelligence has yet to achieve its full potential, meaningful strides are still being made across the drug discovery funnel.


Victoria A. DiBiaso, Beth Brooks, Monique R. Adams

Latest:

Diversity by Design: Combining Strategic Protocol Planning with Accurate Real-world Data

Leveraging a “diversity by design” approach can build patient narratives and optimize protocols from the onset.


Blaise Mwizerwa Nkubito

Latest:

The African Medicines Agency: Impacts on the Continent’s Clinical Trials Regulation

Harmonization could turn the continent into an established site for clinical research and laboratories.


Lauren P. Morgenroth, MS, CGC

Latest:

Rare Disease Clinical Trials: Strategies Learned from Duchenne Muscular Dystrophy

Approaches sponsors, CROs, and investigators can take from the DMD experience.


Laura Iliescu

Latest:

Strategies for Building Greater DE&I in Rare Disease Trials

Outlining new approaches and resources to help ignite progress in this area.


Clinchoice

Latest:

Considerations for Combination Product Registrations in the US and the EU

In this eBook learn about varying categorizations and how they impact combination product registrations in the US and EU markets.


Kathleen Kane

Latest:

Collecting Data from Multiple Study Sites

Case study shows how one CRO ensured high-quality, consistent data in a difficult therapeutic area.


Art Brown

Latest:

How CROs are Uniquely Positioned to Drive Adoption of the TMF Exchange Mechanism

Work across varying therapeutic areas and new technology among reasons why CROs are qualified to advance model.


Komodo

Latest:

The Key to Clinical Trial Success: Patient Tokenization

Wednesday, October 12, 2022 11am PDT | 2pm EDT | 7pm BST | 8pm CEST Real-world-data (RWD) leads to real-world results. Learn how RWD & patient tokenization are streamlining clinical trials and ensuring successful results.


Amit Vasanji, PhD, and Brett A. Hoover

Latest:

Five Critical Qualities for Identifying a Partner to Globally Scale Ophthalmology Clinical Trials

Amplifying the size and diversity of participant pools in clinical trials enhances statistical power and increases the generalizability of study findings.


Alison Holland

Latest:

Seven Ways Clinical Trials Will Look Different by the End of 2021

Changes predicted to change the face of clinical research in 2021.


Saurabh Das

Latest:

AI/ML Approaches to Assisted Medical Writing—Part 2

Following a discussion around summarization in Part 1, Part 2 discusses the method of pure abstraction in light of recent advances in deep learning and AI.


Esther Mahillo

Latest:

Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials

Integrated approaches can help enhance recruitment plans.


Nausheen Saleem

Latest:

eSource Interoperability Between EHR and EDC

Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.


Rohini Kumar

Latest:

Ten Considerations for Sensor Selection in Clinical Trials

The careful selection of sensor technology prioritized in clinical trials, considering regulatory compliance, data security, device characteristics, and the specific needs of the trials for successful and confident implementation.


Meg Rivers

Latest:

From Physician to Pharma: Gynecologic Oncologist Enters Clinical Trials Space

In an interview with Applied Clinical Trials' sister publication, Pharmaceutical Executive, Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses what it was like transitioning from working as a gynecologic oncologist and seeing patients to working in pharma, specifically clinical trials.


Ramona Walls

Latest:

Establishing a Basis for Secondary Use Standards for Clinical Trials

Study seeks to understand how different forms of data meet the needs of researchers.


Robert Paarlberg

Latest:

Clinical Trial Disclosure and Data Transparency: Obligation or Opportunity?

Implementing disclosure and data transparency policies and procedures represents an opportunity for sponsors, rather than an obligation.


Kenny Kong

Latest:

Focus on Fundamentals for Better Collaboration Across Research Sites and Sponsors

Improving the site-sponsor relationship can get trials off on the right foot and on a path for success.


Rhonda Henry

Latest:

The Two Guiding Principles of Optimal Trial Delivery

Trust-based relationships form the foundation for successful trial management.

© 2024 MJH Life Sciences

All rights reserved.